歌礼制药-B（01672.HK）今日盘中大跌9.64%，引发投资者关注。截至发稿，该股报16.5港元，成交额达8.68亿港元。
消息面上，歌礼制药于今日交易时段前发布公告，宣布进行先旧后新配股计划。根据公告，公司控股股东JJW12 Limited将以每股16.45港元的价格配售5240万股现有股份，并认购2882万股新股。配售价较8月18日收市价18.26港元折让约9.9%，这一折价幅度引发了市场的担忧，导致股价下跌。
此次配股所得款项净额预计约为4.68亿港元。公司表示，约90%的资金将用于其皮下注射多肽及口服多肽候选药物有关的肥胖症临床试验研发，剩余约10%将用作营运资金及其他一般公司用途。这一举措显示了公司加大对肥胖症治疗领域研发投入的战略意图，但短期内可能会对股价造成压力。
值得注意的是，此次配售完成后，控股股东JJW12 Limited的持股比例将从约53.38%降至49.45%，控股股东的总持股比例将从约62.21%降至58.03%。尽管控股权未发生根本变化，但持股比例的下降可能引发市场对公司未来发展方向的猜测。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.